The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis

Nature Communications

Volumn 3, Issue , 2012, Pages

  Cudmore, Melissa J ^a   Hewett, Peter W ^b   Ahmad, Shakil ^a   Wang, Ke Qing ^a   Cai, Meng ^a   Al Ani, Bahjat ^c   Fujisawa, Takeshi ^a   Ma, Bin ^a   Sissaoui, Samir ^b   Ramma, Wenda ^a   Miller, Mark R ^a   Newby, David E ^a   Gu, Yuchun ^d   Barleon, Bernhard ^e   Weich, Herbert ^f   Ahmed, Asif ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c KING KHALID UNIVERSITY   (Saudi Arabia)

^d PEKING UNIVERSITY   (China)

^e RELIATech   (Germany)

^f HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HETERODIMER; HOMODIMER; MONOMER; NITRIC OXIDE; PROSTACYCLIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; SMALL INTERFERING RNA;

ARTICLE; CALCIUM MOBILIZATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DIMERIZATION; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HETERODIMERIZATION; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN SECRETION; REGULATORY MECHANISM; VASODILATATION; CELL CULTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; IMMUNOPRECIPITATION; METABOLISM; PROTEIN MULTIMERIZATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOPRECIPITATION; PROTEIN MULTIMERIZATION; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84864856289     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms1977     Document Type: Article

References (59)

1. Shweiki, D., Itin, A., Soffer, D. & Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-848 (1992).
2. Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endoc. Rev. 25, 581-611 (2004). (Pubitemid 39099316)
3. Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439 (1996). (Pubitemid 26102719)
4. Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442 (1996). (Pubitemid 26102720)
5. Miquerol, L., Gertsenstein, M., Harpal, K., Rossant, J. & Nagy, A. Multiple developmental roles of VEGF suggested by a LacZ-Tagged allele. Dev. Biol. 212, 307-322 (1999). (Pubitemid 29387938)
6. Masaki, I. et al. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ. Res. 90, 966-973 (2002). (Pubitemid 34633862)
7. Carmeliet, P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat. Med. 6, 1102-1103 (2000).
8. Lee, R. J. et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102, 898-901 (2000).
9. Springer, M. L., Chen, A. S., Kraft, P. E., Bednarski, M. & Blau, H. M. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol. Cell 2, 549-558 (1998). (Pubitemid 128379081)
10. Ahmed, A. Heparin-binding angiogenic growth factors in pregnancy. Trophoblast. Res. 10, 215-258 (1997).
11. Maynard, S. E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649-658 (2003). (Pubitemid 36278583)
12. Ahmad, S. & Ahmed, A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 95, 884-891 (2004). (Pubitemid 39435003)
13. Kendall, R. L., Wang, G. & Thomas, K. A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226, 324-328 (1996). (Pubitemid 26331903)
14. Ahmed, A., Dunk, C., Kniss, D. & Wilkes, M. Role of VEGF receptor-1 (Flt-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells. Lab. Invest. 76, 779-791 (1997). (Pubitemid 27260345)
15. Rahimi, N., Dayanir, V. & Lashkari, K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J. Biol. Chem. 275, 16986-16992 (2000). (Pubitemid 30398939)
16. Bussolati, B. et al. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am. J. Pathol. 159, 993-1008 (2001). (Pubitemid 32847190)
17. Zeng, H., Zhao, D. & Mukhopadhyay, D. Flt-1-mediated down-regulation of endothelial cell proliferation through pertussis toxin-sensitive G proteins, beta gamma subunits, small GTPase CDC42, and partly by Rac-1. J. Biol. Chem. 277, 4003-4009 (2002). (Pubitemid 34968655)
18. Dunk, C. & Ahmed, A. Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells. Am. J. Pathol. 158, 265-273 (2001). (Pubitemid 32096492)
19. Autiero, M. et al. Role of PlGF in the intra-And intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 9, 936-943 (2003). (Pubitemid 36889938)
20. Covassin, L. D., Villefranc, J. A., Kacergis, M. C., Weinstein, B. M. & Lawson, N. D. Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish. Proc. Natl Acad. Sci. USA 103, 6554-6559 (2006).
21. Prinster, S. C., Hague, C. & Hall, R. A. Heterodimerization of g protein-coupled receptors: specificity and functional significance. Pharmacol. Rev. 57, 289-298 (2005). (Pubitemid 41196951)
22. Barnes, P. J. Receptor heterodimerization: a new level of cross-Talk. J. Clin. Invest. 116, 1210-1212 (2006).
23. Heidaran, M. A. et al. Role of alpha beta receptor heterodimer formation in beta platelet-derived growth factor (PDGF) receptor activation by PDGF-AB. J. Biol. Chem. 266, 20232-20237 (1991). (Pubitemid 21908450)
24. Jorissen, R. N., Treutlein, H. R., Epa, V. C. & Burgess, A. W. Modeling the epidermal growth factor-epidermal growth factor receptor l2 domain interaction: implications for the ligand binding process. J. Biomol. Struct. Dyn. 19, 961-972 (2002). (Pubitemid 34701117)
25. Muthuswamy, S. K., Gilman, M. & Brugge, J. S. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo-And heterodimers. Mol. Cell. Biol. 19, 6845-6857 (1999). (Pubitemid 29441868)
26. Saito, Y. & Berk, B. C. Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors. J. Mol. Cell. Cardiol. 33, 3-7 (2001). (Pubitemid 32127779)
27. Saito, Y., Haendeler, J., Hojo, Y., Yamamoto, K. & Berk, B. C. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol. Cell. Biol. 21, 6387-6394 (2001). (Pubitemid 32927407)
28. Dixelius, J. et al. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J. Biol. Chem. 278, 40973-40979 (2003). (Pubitemid 37280919)
29. Alam, A. et al. Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. Biochem. Biophys. Res. Commun. 324, 909-915 (2004). (Pubitemid 39345601)
30. Nilsson, I. et al. VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. Embo J. 29, 1377-1388 (2010).
31. Kanno, S. et al. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19, 2138-2146 (2000). (Pubitemid 30251379)
32. Huang, K., Andersson, C., Roomans, G. M., Ito, N. & Claesson-Welsh, L. Signaling properties of VEGF receptor-1 and-2 homo-And heterodimers. Int. J. Biochem. Cell Biol. 33, 315-324 (2001). (Pubitemid 32324000)
33. Neagoe, P. E., Lemieux, C. & Sirois, M. G. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and-2 heterodimer. J. Biol. Chem. 280, 9904-9912 (2005). (Pubitemid 40395838)
34. Mac Gabhann, F. & Popel, A. S. Dimerization of VEGF receptors and implications for signal transduction: a computational study. Biophys. Chem. 128, 125-139 (2007). (Pubitemid 46843440)
35. Lin, M. I. & Sessa, W. C. Vascular endothelial growth factor signaling to endothelial nitric oxide synthase: more than a FLeeTing moment. Circ. Res. 99, 666-668 (2006). (Pubitemid 44498299)
36. Imoukhuede, P. I. & Popel, A. S. Quantification and cell-To-cell variation of vascular endothelial growth factor receptors. Exp. Cell Res. 317, 955-965 (2011).
37. Ferre, S. et al. Building a new conceptual framework for receptor heteromers. Nat. Chem. Biol. 5, 131-134 (2009).
38. Mercer, A. A. et al. Vascular endothelial growth factors encoded by Orf virus show surprising sequence variation but have a conserved, functionally relevant structure. J. Gen. Virol. 83, 2845-2855 (2002). (Pubitemid 35276984)
39. Meyer, M. et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. Embo J. 18, 363-374 (1999). (Pubitemid 29041945)
40. Heil, M. et al. An engineered heparin-binding form of VEGF-E (hbVEGF-E). Biological effects in vitro and mobilizatiion of precursor cells. Angiogenesis 6, 201-211 (2003). (Pubitemid 38506665)
41. Seetharam, L. et al. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 10, 135-147 (1995).
42. Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M. & Heldin, C. H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269, 26988-26995 (1994). (Pubitemid 24332901)
43. Neufeld, G. et al. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc. Med. 12, 13-19 (2002). (Pubitemid 34048706)
44. Shen, B. Q., Lee, D. Y., Cortopassi, K. M., Damico, L. A. & Zioncheck, T. F. Vascular endothelial growth factor KDR receptor signaling potentiates tumor necrosis factor-induced tissue factor expression in endothelial cells. J. Biol. Chem. 276, 5281-5286 (2001).
45. Rousseau, S., Houle, F., Landry, J. & Huot, J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15, 2169-2177 (1997). (Pubitemid 27493906)
46. Ahmad, S. et al. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ. Res. 99, 715-722 (2006). (Pubitemid 44498305)
47. Cudmore, M. et al. VEGF-E activates endothelial nitric oxide synthase to induce angiogenesis via cGMP and PKG-independent pathways. Biochem. Biophys. Res. Commun. 345, 1275-1282 (2006). (Pubitemid 43833439)
48. Quinn, T. P., Peters, K. G., De Vries, C., Ferrara, N. & Williams, L. T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl Acad. Sci. USA 90, 7533-7537 (1993). (Pubitemid 23249984)
49. Park, J. E., Chen, H. H., Winer, J., Houck, K. A. & Ferrara, N. Placenta growth factor: potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269, 25646-25654 (1994).
50. Murohara, T. et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest. 101, 2567-2578 (1998). (Pubitemid 28270451)
51. Fukumura, D. & Jain, R. K. Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metastasis Rev. 17, 77-89 (1998). (Pubitemid 28194647)
52. Murohara, T. et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97, 99-107 (1998). (Pubitemid 28036160)
53. Ahmad, S. et al. Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis. Vasc. Cell 3, 15 (2011).
54. Tarallo, V., Tudisco, L. & De Falco, S. A placenta growth factor 2 variant acts as dominant negative of vascular endothelial growth factor A by heterodimerization mechanism. Am. J. Cancer Res. 1, 265-274 (2011).
55. Hauser, S. & Weich, H. A. A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 9, 259-268 (1993). (Pubitemid 24034347)
56. Fiebrich, B. L. et al. Synthesis and assembly of functionally active human vascular endothelial growth factor homodimers in insect cells. Er. J. Biochem. 211, 19-26 (1993).
57. Zhou, C. C. et al. Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ. Res. 100, 88-95 (2007). (Pubitemid 46074969)
58. Hewett, P. W. & Murray, C. Modulation of human endothelial cell procoagulant activity in tumour models in vitro. Int. J. Cancer 66, 784-789 (1996). (Pubitemid 26197947)
59. Miller, M. R. et al. Direct impairment of vascular function by diesel exhaust particulate through reduced bioavailability of endothelium-derived nitric oxide induced by superoxide free radicals. Environ. Health Perspect. 117, 611-616 (2009).